BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 10075528)

  • 1. Hematopoietic stem-cell transplantation for acute leukemia.
    van Bekkum DW; Vriesendorp HM
    N Engl J Med; 1999 Mar; 340(10):809-10; author reply 810-2. PubMed ID: 10075528
    [No Abstract]   [Full Text] [Related]  

  • 2. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
    Strober S
    Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic bone marrow transplantation with non-T-cell-depleted marrow from two HLA-antigen-mismatched related donors.
    Ogawa H; Ikegame K; Kawakami M; Taniguchi Y; Oka Y; Kawase I
    Haematologica; 2004 Mar; 89(3):373-5. PubMed ID: 15020286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hematopoietic stem cell transplantation: 40 years of continuous progress and evolution.
    Porta F; Locatelli F; Burgio GR
    Haematologica; 2008 Nov; 93(11):1607-10. PubMed ID: 18978297
    [No Abstract]   [Full Text] [Related]  

  • 5. [Current status and issues in hematopoietic stem cell transplantation].
    Harada M
    Fukuoka Igaku Zasshi; 2007 Feb; 98(2):35-47. PubMed ID: 17396570
    [No Abstract]   [Full Text] [Related]  

  • 6. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.
    Ruggeri L; Capanni M; Urbani E; Perruccio K; Shlomchik WD; Tosti A; Posati S; Rogaia D; Frassoni F; Aversa F; Martelli MF; Velardi A
    Science; 2002 Mar; 295(5562):2097-100. PubMed ID: 11896281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic blood stem cell transplantation in chronic myeloid leukaemia-chronic phase following conditioning with busulphan and cyclophosphamide: a follow up report.
    Saikia TK; Parikh PM; Tawde S; Amare-Kadam PS; Rajadhyaksha S; Chhaya S
    Natl Med J India; 2004; 17(2):71-3. PubMed ID: 15141598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of AB0-blood group incompatibility on the outcome of recipients of bone marrow transplants from unrelated donors in the Japan Marrow Donor Program.
    Kimura F; Sato K; Kobayashi S; Ikeda T; Sao H; Okamoto S; Miyamura K; Mori S; Akiyama H; Hirokawa M; Ohto H; Ashida H; Motoyoshi K;
    Haematologica; 2008 Nov; 93(11):1686-93. PubMed ID: 18835834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation.
    Huang XJ; Liu DH; Liu KY; Xu LP; Chen H; Han W; Chen YH; Zhang XH; Lu DP
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):257-65. PubMed ID: 19167686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Umbilical cord blood transplantation--how, when and for whom?
    Cohen Y; Nagler A
    Blood Rev; 2004 Sep; 18(3):167-79. PubMed ID: 15183901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of acute graft-vs-host disease by a single low-dose cyclophosphamide injection following allogeneic bone marrow transplantation.
    Prigozhina TB; Elkin G; Khitrin S; Slavin S
    Exp Hematol; 2008 Dec; 36(12):1750-9. PubMed ID: 18809241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A possible association between the presence of interleukin-4-secreting cells and a reduction in the risk of acute graft-versus-host disease.
    Takabayashi M; Kanamori H; Takasaki H; Yamaji S; Koharazawa H; Taguchi J; Tomita N; Fujimaki K; Fujisawa S; Maruta A; Ishigatsubo Y
    Exp Hematol; 2005 Feb; 33(2):251-7. PubMed ID: 15676220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
    Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Graft rejection and hyperacute graft-versus-host disease in stem cell transplantation from non-inherited maternal-antigen-complementary HLA-mismatched siblings.
    Okumura H; Yamaguchi M; Kotani T; Sugimori N; Sugimori C; Ozaki J; Kondo Y; Yamazaki H; Chuhjo T; Takami A; Ueda M; Ohtake S; Nakao S
    Eur J Haematol; 2007 Feb; 78(2):157-60. PubMed ID: 17313562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of acquired a plastic anemia: an update].
    Kojima S
    Rinsho Ketsueki; 2004 Mar; 45(3):202-8. PubMed ID: 15103933
    [No Abstract]   [Full Text] [Related]  

  • 16. Glutathione S-transferase A1 polymorphisms and acute graft-vs.-host disease in HLA-matched sibling allogeneic hematopoietic stem cell transplantation.
    Kim I; Keam B; Lee KH; Kim JH; Oh SY; Ra EK; Yoon SS; Park SS; Kim CS; Park S; Hong YC; Kim BK
    Clin Transplant; 2007; 21(2):207-13. PubMed ID: 17425746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unrelated cord blood transplant as salvage following non-engraftment of unrelated marrow transplant?
    Shaw PJ; Bleakley M; Lau L
    Bone Marrow Transplant; 2004 Aug; 34(3):275-6. PubMed ID: 15156168
    [No Abstract]   [Full Text] [Related]  

  • 18. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
    Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OTI-010 Osiris Therapeutics/JCR Pharmaceuticals.
    Taupin P
    Curr Opin Investig Drugs; 2006 May; 7(5):473-81. PubMed ID: 16729725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new marrow T cell depletion method using anti-CD6 monoclonal antibody-conjugated magnetic beads and its clinical application for prevention of acute graft-vs.-host disease in allogeneic bone marrow transplantation: results of a phase I-II trial.
    Sao H; Kitaori K; Kasai M; Shimokawa T; Kato C; Yamanishi H; Ueda R; Morishima Y
    Int J Hematol; 1999 Jan; 69(1):27-35. PubMed ID: 10641440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.